The primary objective of the study is the evaluation of efficacy of a mouthwash cointaining Chlorexidine (CHX) 0.09% + HA + Citrox (test group) on the quality of wound healing and the presence plaque formation and gingival inflammation in the post-surgical phase. Futhermore stains, discolorations and adverse effects will be eventually recorded. Control group will be represented by the use of a CHX 0.12% mouthwash.
More than 20 natural teeth excluding the third molars
Clinical indication for a surgical intervention for the treatment of at least one residual pocket after non-surgical therapy (pocket depth (PD) ≥5mm)
Have a full mouth plaque score (FMPS) <15% before surgery;
Have a full mouth bleeding score (FMBS) <15% before surgery;
Use of medications, such as anti-platelet or anti-coagulant agents, any other concomitant systemic disorder, cardiovascular and diabetes diseases, allergic, infectious diseases and medications affecting periodontal inflammation
Pregnancy or breastfeeding;
Use of medication affecting the healing process;
Assumption of systemic or local antibiotics in the 4 weeks before trial beginning;
Parallel
CHX 0.09% + Citrox + HA
Other interventionThe patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
CHX 0.12%
DrugThe patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
Oedema
Presence of absence will be recorded (1 or 0).
Early Healing Score
The score comprises three parameters (Clinical signs of re-epithelialization, hemostasis and inflammation) and ranges from 0 (worst healing) to 10 (best healing)
Plaque Index modified by Turesky
Gingival Index modified by Trombelli
Lobene Index modified
Presence of stains or discolorations of teeth and mucosae
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
